Effects of sarpogrelate on microvascular complications with type 2 diabetes

No abstract is available for this paper.

• Publication year

  2019

• Venue

  International Journal of Clinical Pharmacy

• Publication date

  2019-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11096-019-00794-7PMID 30864083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival Analysis

  2022cited by this paper
• SURVIVAL ANALYSIS

  2020cited by this paper
• Diabetes care

  2019cited by this paper
• IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

  2018cited by this paper
• A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.

  2017cited by this paper
• 6. Glycemic Targets: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes.

  2017cited by this paper
• Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice

  2017cited by this paper
• Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: A national cohort study

  2017cited by this paper
• Introduction: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• Liraglutide and Renal Outcomes in Type 2 Diabetes

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Disability-adjusted Life Years for 313 Diseases and Injuries: the 2012 Korean Burden of Disease Study

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Trends in Diabetes Incidence in the Last Decade Based on Korean National Health Insurance Claims Data

  2016cited by this paper
• Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013

  2016cited by this paper
• Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging

  2014cited by this paper
• Renal outcomes in patients with type 1 diabetes and macroalbuminuria.

  2014cited by this paper
• The potential for renoprotection with incretin-based drugs.

  2014cited by this paper
• Is a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?

  2014cited by this paper
• Mechanisms of diabetic complications.

  2013cited by this paper
• A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.

  2013cited by this paper
• Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase‐4 inhibitors and sulphonylureas: a primary care database analysis

  2013cited by this paper
• Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

  2013cited by this paper
• KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

  2012cited by this paper
• Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

  2012cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Changes in albuminuria predict mortality and morbidity in patients with vascular disease.

  2011cited by this paper
• Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

  2010cited by this paper
• Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization.

  2008cited by this paper
• Surrogate end points for clinical trials of kidney disease progression.

  2006cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  2004cited by this paper
• Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.

  2002cited by this paper
• Model‐Checking Techniques Based on Cumulative Residuals

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper

• Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial.

  2024cites this paper
• Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes.

  2024cites this paper
• Dysregulated coagulation system links to inflammation in diabetic kidney disease

  2023cites this paper
• The Role of Platelets in Diabetic Kidney Disease

  2022cites this paper
• A systematic review of statistical methodology used to evaluate progression of chronic kidney disease using electronic healthcare records

  2022cites this paper
• Management of Intractable Painful Diabetic Peripheral Neuropathy: The Perspective of a Pain Specialist

  2022cites this paper
• Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?

  2020cites this paper
• Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

  2020cites this paper
• Clinical Outcomes of Antiplatelets Combined with Statins in Patients with Ischemic Heart Disease

  2019cites this paper
• Blockade of 5‐HT2 receptors with sarpogrelate uncovers 5‐HT7 receptors inhibiting the tachycardic sympathetic drive in pithed rats

  2019cites this paper